TP53 and cancer: These growth inhibitory functions are frequently lost during tumorigenesis, most commonly through direct mutations in the p53 gene, which occur in ~50% of all human cancer cases.5 However, in the remaining cases, p53 status remains wild type (wt) and its function and/or expression is compromised by other mechanisms.